Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial

WANG Shu-sen; YU Hong-yan

doi:10.3969/j.issn.1671-5144.2015.03.009

WANG Shu-sen, YU Hong-yan. Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 146-148. DOI: 10.3969/j.issn.1671-5144.2015.03.009

Citation:

WANG Shu-sen, YU Hong-yan. Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 146-148. DOI: 10.3969/j.issn.1671-5144.2015.03.009

Citation:

WANG Shu-sen, YU Hong-yan. Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial[J]. Journal of Evidence-Based Medicine, 2015, 15(3): 146-148. DOI: 10.3969/j.issn.1671-5144.2015.03.009

Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial

Graphical Abstract

Abstract

FullText(HTML)

References (0)

Palbociclib in Combination with Letrozole Versus Letrozole alone as First-Line Treatment of Oestrogen Receptor Positive, HER2-Negative, Advanced Breast Cancer Significantly Improve Progression-Free Survivial

Catalog

Export File

Citation

Format

Content